Traduction de «agent à usage nasal » (Français → Anglais) :

13. Deeply regrets the loss of life among protesters and police, the excessive use of force by police and the violent acts by some marginal groups; takes the view that the protests in Gezi Park testify both to the existence in Turkey of a vibrant civil society and to the need for further vital dialogue and reforms, as a matter of urgency, on the promotion of fundamental values; considers regrettable the apparent failure of the courts to penalise all those state officials and police officers responsible for excessive violence, loss of life, and serious injuries to Gezi Park protesters, and therefore welcomes the ongoing administrative investigations (launched by the Ministry of the Interior), the judicial investigations and the inquiries b ...[+++]y the Ombudsman into complaints relating to the events in Gezi Park, as a new opportunity to show full commitment to the rule of law and bring those responsible to justice; expects these investigations and inquiries to address the concerns fully and without delay; calls on Turkey to adopt adequate internal review procedures and to establish an independent supervisory body for police offences; takes the view that the Gezi Park events underline the need for far-reaching reforms in order to ensure respect for freedom of assembly; encourages the Ministry of the Interior and the police to establish methods for dealing with public protests in a more restrained way and calls on them, in particular, not to arrest or hinder the work of medical staff, lawyers and other professionals ensuring the basic rights of protesters; is concerned about the action taken against health professionals, lawyers, academics, students and professional associations in connection with their non-violent actions during the Gezi events;

AP. whereas development of resistance to antimicrobial agents is a natural and unavoidable consequence of their use, but whereas it can be limited if they are used prudently and rationally;

Günter Verheugen, Vice-President of the Commission (DE) Considering the risks of substances that are carcinogenic, mutagenic, or toxic to reproduction, the Commission shall appoint the Committee for Medicinal Products for Human Use of the European Agency for the Evaluation of Medicinal Products to formulate an opinion on the use of these categories of substance as auxiliary agents in medicinal products for human use; the legal basis for this is Article 5(3) and Article 57(1)(p) of Regulation (EC) No 726/2004 of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veteri ...[+++]nary use and establishing a European Medicines Agency.

Specific measures concerning the prevention of the transmission of animal spongiform encephalopathies (materials from ruminant origin): at each step of the manufacturing process, the applicant must demonstrate the compliance of the materials used with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Medicinal Products and its updates, published by the Commission in the Official Journal of the European Union.

Regarding the specific measures for the prevention of the Transmission of animal Spongiform Encephalopathies, the applicant must demonstrate that the active substance complies with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Medicinal Products and its updates, published by the Commission in the Official Journal of the European Union.

Regarding the specific measures for the prevention of the Transmission of animal Spongiform Encephalopathies, the applicant must demonstrate also for excipients that the medicinal product is manufactured in accordance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Medicinal Products and its updates, published by the Commission in the Official Journal of the European Union.